Rupee Payments for Indian Pharmaceutical Imports

India’s Pharmaceutical Exports Surge: Targeting $130 Billion Sector by 2030

India continues to solidify its position as a global powerhouse in pharmaceutical production, maintaining a steady growth trajectory despite significant global economic headwinds. Recent data reveals that the sector is not only expanding its export footprint but is similarly eyeing a massive valuation increase, with projections suggesting the industry could more than double in size by the complete of the decade.

Current Export Performance in FY26

According to K Raja Bhanu, Director General of the Pharmaceuticals Export Promotion Council of India (Pharmexcil), India’s pharmaceutical exports reached $28.29 billion during the period of April to February in FY26. This represents a 5.6% increase compared to the same period in FY25.

This growth has been primarily driven by several key product categories, including:

• Pharmaceutical formulations
• Biologicals
• Vaccines
• AYUSH products

This momentum follows a strong FY2024-25, where exports hit $30.47 billion, marking a 9.4% year-on-year growth despite volatility in trade and global pricing pressures.

The Roadmap to 2030: Scaling Up

The Indian pharmaceutical sector, currently valued at approximately $60 billion, is projected to grow to $130 billion by 2030. To support this expansion, Pharmexcil has set an ambitious export target of $65 billion by 2030.

Industry leaders indicate that this growth will be underpinned by several strategic pillars:

• Policy Prioritization: Increased government focus on scaling exports.
• Market Diversification: Expanding reach beyond traditional trading partners.
• Investment: Higher inflows of Foreign Direct Investment (FDI).
• Efficiency: Faster regulatory clearances to streamline shipments.

Global Market Reach and Compliance

India currently ranks third globally in pharmaceutical production by volume, with its products reaching more than 200 different markets. A significant indicator of the sector’s quality and compliance standards is that over 60% of these exports are destined for highly regulated markets.

The distribution of these exports is heavily concentrated in two primary regions:

• United States: Accounts for 34% of India’s pharmaceutical exports.
• Europe: Accounts for 19% of exports.

The Currency Dynamic: Dollars vs. Rupees

While meeting specific targets in U.S. Dollar terms can be challenging due to global economic shifts, the sector’s growth is often reflected differently in local currency. Rajesh Agrawal, Secretary in the Department of Commerce, noted that exports are likely to show growth in rupee terms due to the fact that the Indian currency continues to weaken against the U.S. Dollar.

Agrawal acknowledged that while certain dollar-denominated targets appear difficult to meet, the overall trajectory of the industry remains positive.

Key Takeaways: India’s Pharma Outlook

As India continues to scale its production of biologicals and vaccines while diversifying its market reach, the sector is well-positioned to maintain its momentum as a critical supplier to the global healthcare ecosystem.